Mesothelioma
A multicenter study that included 21,062 patients who were seen from 2009-2021 in South Korea provided key insights.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
Despite decades of decline, "lung cancer continues to dwarf other cancers in the number of deaths," officials said.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
A new study illustrated the importance of exercise for patients with lung cancer who experience cancer-related fatigue.
Certain groups continue to experience higher rates of lung cancer mortality related to chronic lower respiratory diseases.
Researchers evaluated the immunogenicity and safety of the COVID-19 vaccine in patients with lung cancer.
The recent report shows that the "breadth of tobacco-caused disparities continues to persist and expand."
The last Surgeon General’s report on tobacco-related disparities was released more than two decades ago in 1998.
A project led by a researcher from the Dana-Farber Cancer Center is the first to receive the four-year grant of $2.5 million.
Deborah Brown shares key findings from the recently released seventh annual "State of Lung Cancer" report.
The campaign kicked off on November 1 to coincide with Lung Cancer Awareness Month.
Deborah Brown shares how the American Lung Association and its LUNG FORCE initiative are raising awareness this month.
Dr. Studts discusses why Lung Cancer Awareness Month is a critical time to inspire action, engagement, and hope.
The initiative is promoting lung cancer screening and efforts to fund research, as well as releasing an upcoming report.
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
Lung Cancer Awareness Month is observed every November and represents a key time to take action and raise awareness.
The campaign, titled "Anyone with Lungs Can Get Lung Cancer," includes multiple virtual and in-person components.
Arthi Sridhar, MD, discusses the real-world study, which was presented at the IASLC 2024 World Conference on Lung Cancer.
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
The registry, launched by the Florez Lab in 2023, is collecting data from around the world.
Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer.
Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing.
Dr. Gieske shares what the White Ribbon Project means to him as a lung cancer clinician.
Researchers presented results from the randomized controlled trial of mPATH-Lung at the CHEST Annual Meeting.
Jamie L. Studts, PhD, discusses the use of the QUILS™ system in Kentucky and the importance of community engagement.
Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study.
Jill Feldman, a patient advocate, discusses how the lexicon can improve communication and empower patients.
The KEYNOTE-483 trial showed a significant improvement in OS with the addition of pembrolizumab to chemotherapy.
Martin Reck, MD, PhD, shares his insights on key data in lung cancer to be presented at the ESMO Congress 2024.
Narjust Florez, MD, FASCO, discusses meeting highlights, the IASLC 50th Anniversary Celebration, research, and more.
Researchers used data from the Thoracic Tumors Registry to conduct 2 analyses using artificial intelligence.
The intervention included psychoeducation, relaxation training, and behavioral techniques for managing acute breathlessness.
Eric Singhi, MD, discusses the key milestone that will be celebrated at the conference, which will be held in San Diego.
Learn how clinicians can take practical steps to ensure patients with lung cancer receive comprehensive biomarker testing.
Recent data show that less than half of patients are receiving biomarker testing results before starting treatment.
The study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer.
World Lung Cancer Day is marked on August 1 annually.
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
A pilot study evaluated neoadjuvant platinum, pemetrexed, and nivolumab followed by pleurectomy/decortication.
Nearly 80% of patients enrolled had epithelioid histology and 65% had an ECOG performance status of 1.
Researchers evaluated the combination in an effort to “further enhance the immunogenicity" of the vaccine.
Occupational asbestos exposure leads to shorter survival in patients with malignant mesothelioma.
Guideline-concordant therapy remains underused in most mesothelioma patients.
A complete residential history should be reviewed following a mesothelioma diagnosis.
Radiation therapy with HT is safe and effective in patients with malignant pleural mesothelioma.
Analyzing the exhaled breath of patients with mesothelioma shows tremendous potential as a screening tool.
Krebs von den Lungen-6 is a potential novel diagnostic and prognostic biomarker in pleural mesothelioma.
A simple blood draw could help predict survival outcomes in patients with malignant pleural mesothelioma.
Advertisement
Expert Interviews on Lung Cancer
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.